Search

Your search keyword '"Coll, Jean-Luc"' showing total 856 results
Start Over Author "Coll, Jean-Luc"
856 results on '"Coll, Jean-Luc"'

51. Supplementary Methods and Materials from ZNF217 Is a Marker of Poor Prognosis in Breast Cancer That Drives Epithelial–Mesenchymal Transition and Invasion

Author

Vendrell, Julie A., primary, Thollet, Aurélie, primary, Nguyen, Nhan T., primary, Ghayad, Sandra E., primary, Vinot, Stéphanie, primary, Bièche, Ivan, primary, Grisard, Evelyne, primary, Josserand, Véronique, primary, Coll, Jean-Luc, primary, Roux, Pierre, primary, Corbo, Laura, primary, Treilleux, Isabelle, primary, Rimokh, Ruth, primary, and Cohen, Pascale A., primary

Published
2023
Full Text
View/download PDF

52. Supplementary Figures 1-10 from ZNF217 Is a Marker of Poor Prognosis in Breast Cancer That Drives Epithelial–Mesenchymal Transition and Invasion

Author

Vendrell, Julie A., primary, Thollet, Aurélie, primary, Nguyen, Nhan T., primary, Ghayad, Sandra E., primary, Vinot, Stéphanie, primary, Bièche, Ivan, primary, Grisard, Evelyne, primary, Josserand, Véronique, primary, Coll, Jean-Luc, primary, Roux, Pierre, primary, Corbo, Laura, primary, Treilleux, Isabelle, primary, Rimokh, Ruth, primary, and Cohen, Pascale A., primary

Published
2023
Full Text
View/download PDF

53. Suppl. Movie 3 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

54. Supp. Figure 1 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

55. Supp. Figure 5 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

56. Supp. Figure 7 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

57. Data from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

58. Supplementary Tables 1-6 from ZNF217 Is a Marker of Poor Prognosis in Breast Cancer That Drives Epithelial–Mesenchymal Transition and Invasion

Author

Vendrell, Julie A., primary, Thollet, Aurélie, primary, Nguyen, Nhan T., primary, Ghayad, Sandra E., primary, Vinot, Stéphanie, primary, Bièche, Ivan, primary, Grisard, Evelyne, primary, Josserand, Véronique, primary, Coll, Jean-Luc, primary, Roux, Pierre, primary, Corbo, Laura, primary, Treilleux, Isabelle, primary, Rimokh, Ruth, primary, and Cohen, Pascale A., primary

Published
2023
Full Text
View/download PDF

59. Suppl. Movie 1 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

60. Supp. Figure 6 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

61. NIR-II Aza-BODIPY Dyes Bioconjugated to Monoclonal Antibody Trastuzumab for Selective Imaging of HER2-Positive Ovarian Cancer

Author

Godard, Amélie, primary, Kalot, Ghadir, additional, Privat, Malorie, additional, Bendellaa, Mohamed, additional, Busser, Benoit, additional, Wegner, K. David, additional, Denat, Franck, additional, Le Guével, Xavier, additional, Coll, Jean-Luc, additional, Paul, Catherine, additional, Bodio, Ewen, additional, Goze, Christine, additional, and Sancey, Lucie, additional

Published
2023
Full Text
View/download PDF

63. Augmented interaction of multivalent arginine coated gold nanoclusters with lipid membranes and cells

Author

Porret, Estelle, Fleury, Jean-Baptiste, Sancey, Lucie, Pezet, Mylène, Coll, Jean-Luc, Le Guével, Xavier, Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) (IAB), Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Saarland University [Saarbrücken], and Sancey, Lucie

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], mental disorders, behavioral disciplines and activities
Abstract

International audience; A library of ultra-small red photoluminescent gold nanoclusters (Au NCs) were synthesized with an increasing amount of positive charges provided by the addition of mono-, di-or trivalent-glutathione modified arginine peptides. We then studied how the arginine content impacted on the interaction of Au NCs with negatively charged artificial lipid bilayers and cell membranes. Results indicated that increasing the arginine content enhanced Au NCs' adsorption on lipid bilayers and on cell membranes followed by an increased cellular uptake in melanoma cells (COLO 829). Surprisingly, the presence of up to 40% serum for highly positively charged Au NCs did not hinder their interaction with lipid bilayers that contain glycolipids, suggesting a reduced opsonization of these Au NCs. In addition, these Au NCs are usually not toxic, except those with the highest arginine contents. Thus, controlled grafting of arginine peptides onto Au NCs is an elegant strategy to improve their binding and internalization by tumor cells while still keeping their anti-fouling properties.

Published
2023
Full Text
View/download PDF

64. Intracellular accumulation and immunological response of NIR-II polymeric nanoparticles

Author

Moskalevska, Iryna, primary, Faure, Virginie, additional, Haye, Lucie, additional, Mercey-Ressejac, Marion, additional, Dey, Arindam K., additional, Chovelon, Benoit, additional, Soro, Lohona K., additional, Charbonnière, Loïc J., additional, Reisch, Andreas, additional, Klymchenko, Andrey S., additional, Marche, Patrice N., additional, Coll, Jean-Luc, additional, Macek Jilkova, Zuzana, additional, and le Guével, Xavier, additional

Published
2023
Full Text
View/download PDF

90. Lipoprotein interactions with water-soluble NIR-II emitting aza-BODIPYs boost the fluorescence signal and favor selective tumor targeting

Author

Kalot, Ghadir, primary, Godard, Amélie, additional, Busser, Benoit, additional, Bendellaa, Mohamed, additional, Dalonneau, Fabien, additional, Paul, Catherine, additional, Le Guével, Xavier, additional, Josserand, Véronique, additional, Coll, Jean-Luc, additional, Denat, Franck, additional, Bodio, Ewen, additional, Goze, Christine, additional, Gautier, Thomas, additional, and Sancey, Lucie, additional

Published
2022
Full Text
View/download PDF

91. FGF-2 promotes angiogenesis through a SRSF1/SRSF3/SRPK1-dependent axis that controls VEGFR1 splicing in endothelial cells

Author

Jia, Tao, Jacquet, Thibault, Dalonneau, Fabien, Coudert, Pauline, Vaganay, Elisabeth, Exbrayat-Héritier, Chloé, Vollaire, Julien, Josserand, Véronique, Ruggiero, Florence, Coll, Jean-Luc, Eymin, Béatrice, Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) (IAB), Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Sichuan University [Chengdu] (SCU), Institut de Génomique Fonctionnelle de Lyon (IGFL), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Malbec, Odile, and École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL)

Subjects
Lung Neoplasms, Neovascularization, Pathologic, Serine-Arginine Splicing Factors, QH301-705.5, [SDV]Life Sciences [q-bio], Protein Serine-Threonine Kinases, endothelial cells, Angiogenesis/endothelial cells/fibroblast growth factor/VEGFR1/SR proteins, [SDV] Life Sciences [q-bio], Mice, VEGFR1, fibroblast growth factor, RNA Precursors, Animals, Humans, Fibroblast Growth Factor 2, Angiogenesis, Biology (General), Zebrafish, SR proteins, Research Article
Abstract

Background Angiogenesis is the process by which new blood vessels arise from pre-existing ones. Fibroblast growth factor-2 (FGF-2), a leading member of the FGF family of heparin-binding growth factors, contributes to normal as well as pathological angiogenesis. Pre-mRNA alternative splicing plays a key role in the regulation of cellular and tissular homeostasis and is highly controlled by splicing factors, including SRSFs. SRSFs belong to the SR protein family and are regulated by serine/threonine kinases such as SRPK1. Up to now, the role of SR proteins and their regulators in the biology of endothelial cells remains elusive, in particular upstream signals that control their expression. Results By combining 2D endothelial cells cultures, 3D collagen sprouting assay, a model of angiogenesis in cellulose sponges in mice and a model of angiogenesis in zebrafish, we collectively show that FGF-2 promotes proliferation, survival, and sprouting of endothelial cells by activating a SRSF1/SRSF3/SRPK1-dependent axis. In vitro, we further demonstrate that this FGF-2-dependent signaling pathway controls VEGFR1 pre-mRNA splicing and leads to the generation of soluble VEGFR1 splice variants, in particular a sVEGFR1-ex12 which retains an alternative last exon, that contribute to FGF-2-mediated angiogenic functions. Finally, we show that sVEGFR1-ex12 mRNA level correlates with that of FGF-2/FGFR1 in squamous lung carcinoma patients and that sVEGFR1-ex12 is a poor prognosis marker in these patients. Conclusions We demonstrate that FGF-2 promotes angiogenesis by activating a SRSF1/SRSF3/SRPK1 network that regulates VEGFR1 alternative splicing in endothelial cells, a process that could also contribute to lung tumor progression. Supplementary Information The online version contains supplementary material available at 10.1186/s12915-021-01103-3.

Published
2021
Full Text
View/download PDF

95. Étude multiparamétrique de la bio-toxicité et bio-distribution des nanoparticules AGuIX® sur des modèles innovants de cultures 3D MucilAirTM et OncoCilAirTM

Author

Boudard, Delphine, primary, Sancey, Lucie, additional, Sabido, Odile, additional, He, Zhiguo, additional, Rossetti, Fabien, additional, Guignandon, Alain, additional, Bin, Valérie, additional, Coll, Jean-Luc, additional, Cottier, Michele, additional, Lux, François, additional, Tillement, Olivier, additional, Constant, Samuel, additional, and Mas, Christophe, additional

Published
2021
Full Text
View/download PDF

98. Additional file 2 of FGF-2 promotes angiogenesis through a SRSF1/SRSF3/SRPK1-dependent axis that controls VEGFR1 splicing in endothelial cells

Author

Jia, Tao, Jacquet, Thibault, Dalonneau, Fabien, Coudert, Pauline, Vaganay, Elisabeth, Exbrayat-Héritier, Chloé, Vollaire, Julien, Josserand, Véronique, Ruggiero, Florence, Coll, Jean-Luc, and Eymin, Béatrice

Abstract

Additional File 2: Figure S2. Schematic representation of VEGFR1 and VEGFR1 splice variants. sVEGFR1-ex15a results from activation of a cryptic 3’-splice acceptor site upon the use of an alternative polyadenylation site in the latter half of intron 14. sVEGFR1-i13 short and sVEGFR1-i13 long result from alternative polyadenylation at different sites in intron 13 to yield mRNAs encoding the same 867 amino acid sVEGFR1 protein isoform, but with either a 17 or 4146 nt 3’-UTR region. sVEGFR1-ex12 retains an alternative last exon (exon 12). The location of forward and reverse primers used in RT-PCR analyses are indicated as black arrows on each transcript. siRNA sequences target exon 12 for sVEGFR1-ex12 and the junction between exon 13 and retained intron 13 for sVEGFR1-i13. (PPTX 68 kb)

Published
2021
Full Text
View/download PDF

99. Additional file 1 of FGF-2 promotes angiogenesis through a SRSF1/SRSF3/SRPK1-dependent axis that controls VEGFR1 splicing in endothelial cells

Author

Jia, Tao, Jacquet, Thibault, Dalonneau, Fabien, Coudert, Pauline, Vaganay, Elisabeth, Exbrayat-Héritier, Chloé, Vollaire, Julien, Josserand, Véronique, Ruggiero, Florence, Coll, Jean-Luc, and Eymin, Béatrice

Abstract

Additional File 1: Figure S1. Effects of FGFR (AZD4547) and SRPK1 (SRPIN340, SPHINX31) inhibitors on VEGF165b protein and total VEGF-A, VEGF121, VEGF165 and VEGF189 mRNA levels in endothelial cells treated or not with FGF-2. (a) Representative VEGF165b immunoblots in HUVEC and HDMEC treated or not (NT) for 72 hours with 3nM FGF-2 in the presence or absence of 10nM AZD4547 (FGFRinh), 10μM SRPIN340 or 5μM SPHINX31 as indicated. GAPDH was used as a loading control. Representative immunoblots of two (HUVEC) and three (HDMEC) independent experiments are presented. (b) HDMEC cells were treated (FGF) or not (NT) with 3nM FGF-2 for 72 hours in the presence or absence of 5μM SPHINX31 (SPH31) or 10μM SRPIN340 as indicated. Graphs represent mean values ± SD of normalized expression of each transcript according to GAPDH mRNA level in 3 independent experiments. For each transcript, the fold change was calculated with value 1 assigned to the normalized expression value obtained in the non treated (control) condition. Unpaired t test, *p

Published
2021
Full Text
View/download PDF

100. Two Antagonistic Microtubule Targeting Drugs Act Synergistically to Kill Cancer Cells

Author

Peronne, Lauralie, Denarier, Eric, Rai, Ankit, Prudent, Renaud, Vernet, Audrey, Suzanne, Peggy, Ramirez-Rios, Sacnicté, Michallet, Sophie, Guidetti, Mélanie, Vollaire, Julien, Lucena-Agell, Daniel, Ribba, Anne-Sophie, Josserand, Véronique, Coll, Jean-Luc, Dallemagne, Patrick, Díaz, J Fernando, Oliva, María Ángela, Sadoul, Karin, Akhmanova, Anna, Andrieux, Annie, Lafanechère, Laurence, Sub Cell Biology, and Celbiologie

Subjects
microtubules, paclitaxel, drug synergy, carbazole, cancer therapy
Abstract

Paclitaxel is a microtubule stabilizing agent and a successful drug for cancer chemotherapy inducing, however, adverse effects. To reduce the effective dose of paclitaxel, we searched for pharmaceutics which could potentiate its therapeutic effect. We screened a chemical library and selected Carba1, a carbazole, which exerts synergistic cytotoxic effects on tumor cells grown in vitro, when co-administrated with a low dose of paclitaxel. Carba1 targets the colchicine binding-site of tubulin and is a microtubule-destabilizing agent. Catastrophe induction by Carba1 promotes paclitaxel binding to microtubule ends, providing a mechanistic explanation of the observed synergy. The synergistic effect of Carba1 with paclitaxel on tumor cell viability was also observed in vivo in xenografted mice. Thus, a new mechanism favoring paclitaxel binding to dynamic microtubules can be transposed to in vivo mouse cancer treatments, paving the way for new therapeutic strategies combining low doses of microtubule targeting agents with opposite mechanisms of action.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results